MCM
AVBP icon

MAI Capital Management’s ArriVent BioPharma AVBP Stock Holding History

MAI Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439 Buy
+19
New +$429 ﹤0.01% 4448

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MAI Capital Management's AVBP Position: Q1 2026 in Review

MAI Capital Management opened a new position in ArriVent BioPharma (AVBP) in Q1 2026: 19 shares worth $439. The stake represents ﹤0.01% of the portfolio and ranks #4448 among its holdings.

139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • MAI Capital Management held 19 shares of ArriVent BioPharma worth $439 as of Q1 2026.
  • ArriVent BioPharma was a new MAI Capital Management position in Q1 2026.
  • ArriVent BioPharma made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4448 holding.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.